Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Raises Full-Year Revenue Guidance After Strong Q3 Performance
Summary
Vertex Pharmaceuticals Incorporated reported a 12% increase in product revenue for Q3 2024, driven by strong sales of TRIKAFTA. The company raised its full-year product revenue guidance to $10.8 billion to $10.9 billion, reflecting continued growth and the successful progress of its product pipeline. Vertex's full financial results and additional details are available in the attached press release.
Profitelligence Alerts
Get alerts for VRTX
Be first to know when Vertex Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.
Official SEC Documents
Advertisement